文献速递慢性肾脏病遗传性与小管间质肾病

骨质疏松与慢性肾脏病-矿物质和骨异常(CKD-MBD):回归基础

Osteoporosis and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Back to Basics.
PubMed 文献 · Am J Kidney Dis · 2021-03-25

本文综述骨质疏松与CKD-MBD的关系,指出骨质疏松仅是CKD相关骨并发症谱的一部分,组织学上CKD所致改变不满足骨质疏松诊断。提出「CKD-MBD/骨质疏松」术语可能更合适,并讨论诊断需骨活检排除其他肾性骨病,治疗上抗骨质疏松药在CKD 3b-5期高危患者中超说明书使用。

要点

  • 骨质疏松仅为CKD相关骨并发症谱的一部分,不能涵盖肾性骨营养不良等类型。
  • 「CKD-MBD/骨质疏松」可能比「肾性骨质疏松」更合适,后者组织学上不成立。
  • 无创检查无法鉴别骨质疏松与各型肾性骨营养不良,髂骨活检可诊断但可及性有限。

核心结论

  • 骨质疏松与CKD-MBD是谱系关系,CKD所致骨改变组织学上不满足骨质疏松诊断。
  • 「CKD-MBD/骨质疏松」术语可能更合适,有助于诊断与治疗决策。
  • FDA未批准任何抗骨折药物用于肾性骨病患者,现有药物均为超说明书使用。

研究设计与样本

  • 综述性文章,基于骨组织学、诊断分类与治疗证据汇总。
  • 未报告系统检索范围或样本量。

主要发现

  • 骨质疏松定义基于骨强度下降致骨折风险升高,但组织学上仅覆盖部分骨并发症谱。
  • CKD相关骨改变包括骨软化症及各型肾性骨营养不良,组织学诊断不满足骨质疏松标准。
  • 基于骨转换(低至高)、矿化与骨体积的代谢性骨病分类已被提出。
  • 抑制PTH药物(维生素D类似物与拟钙剂)用于治疗高PTH骨病。
  • 抗骨吸收与骨合成代谢药在CKD 3b-5期高危患者中超说明书使用。

关键数值与推荐

  • 骨质疏松诊断需髂骨活检排除其他肾性骨病,但可及性有限。
  • CKD 3b-5期高危患者可超说明书使用抗骨质疏松药物。
  • 有建议CKD 2期即可间歇使用PTH,尚待临床试验证实。

临床怎么用

  • 临床应区分骨质疏松与肾性骨营养不良,避免混淆术语影响治疗决策。
  • 对CKD合并骨质疏松高危患者,可考虑超说明书使用抗骨吸收或骨合成代谢药。
  • CKD早期(2期)间歇PTH治疗可能减少磷潴留及FGF23升高,但需试验验证。

局限性

  • 综述未报告系统检索策略与证据等级。
  • 骨活检可及性有限,限制组织学诊断的临床应用。
  • 抗骨质疏松药在CKD人群中的疗效与安全性缺乏FDA批准证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Osteoporosis is defined as a skeletal disorder of compromised bone strength predisposing those affected to an elevated risk of fracture. However, based on bone histology, osteoporosis is only part of a spectrum of skeletal complications that includes osteomalacia and the various forms of renal osteodystrophy of chronic kidney disease-mineral and bone disorder (CKD-MBD). In addition, the label "kidney-induced osteoporosis" has been proposed, even though the changes caused by CKD do not qualify as osteoporosis by the histological diagnosis. It is clear, therefore, that such terminology may not be helpful diagnostically or in making treatment decisions. A new label, "CKD-MBD/osteoporosis" could be a more appropriate term because it brings osteoporosis under the official label of CKD-MBD. Neither laboratory nor noninvasive diagnostic investigations can discriminate osteoporosis from the several forms of renal osteodystrophy. Transiliac crest bone biopsy can make the diagnosis of osteoporosis by exclusion of other kidney-associated bone diseases, but its availability is limited. Recently, a classification of metabolic bone diseases based on bone turnover, from low to high, together with mineralization and bone volume, has been proposed. Therapeutically, no antifracture treatments have been approved by the US Food and Drug Administration for patients with kidney-associated bone disease. Agents that suppress parathyroid hormone (vitamin D analogues and calcimimetics) are used to treat hyperparathyroid bone disease. Antiresorptive and osteoanabolic agents approved for osteoporosis are being used off-label to treat CKD stages 3b-5 in high-risk patients. It has now been suggested that intermittent administration of parathyroid hormone as early as CKD stage 2 could be an effective management strategy. If confirmed in clinical trials, it could mitigate the retention of phosphorus and subsequently the rise in fibroblast growth factor 23 and may be beneficial for coexisting osteoporosis.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Pazianas M, Miller PD. Osteoporosis and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Back to Basics. Am J Kidney Dis. 2021. PMID: 33774081. doi:10.1053/j.ajkd.2020.12.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。